- Home
- PONO vs KZIA Comparison
PONO vs KZIA Comparison
Compare PONO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PONO | KZIA |
|---|---|---|
| Founded | 2026 | 1994 |
| Country | Cayman Islands | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 186.7M |
| IPO Year | 2026 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PONO | KZIA |
|---|---|---|
| Price | $10.02 | $7.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 62.0K | ★ 229.9K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.95 | $4.86 |
| 52 Week High | $10.09 | $17.40 |
Technical Indicators
Market Signals| Indicator | PONO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 37.13 |
| Support Level | $10.02 | $6.72 |
| Resistance Level | $10.09 | $8.18 |
| Average True Range (ATR) | 0.01 | 0.68 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 37.50 | 40.26 |
Price Performance
Historical ComparisonAbout PONO Pono Capital Four Inc. Class A Ordinary Shares
Pono Capital Four Inc is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.